Suven Pharmaceuticals Limited (SUVENPHAR.BO)
INR 1222.9
(-1.92%)
INR 1222.9
(-1.92%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 144.97 Million INR | 161.78% |
| 2022 | 55.38 Million INR | -89.46% |
| 2021 | 525.63 Million INR | -61.31% |
| 2020 | 1.35 Billion INR | -22.15% |
| 2019 | 1.74 Billion INR | 142.75% |
| 2018 | 718.9 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | 4.86 Billion INR | 8692.87% |
| 2023 Q2 | -67.89 Million INR | -101.39% |
| 2023 FY | 144.97 Million INR | 161.78% |
| 2023 Q3 | -7.19 Billion INR | -10489.26% |
| 2023 Q4 | 144.97 Million INR | 102.02% |
| 2022 Q1 | 5.25 Billion INR | 900.29% |
| 2022 FY | 55.38 Million INR | -89.46% |
| 2022 Q4 | 55.38 Million INR | -98.66% |
| 2022 Q3 | 4.12 Billion INR | 1555.19% |
| 2022 Q2 | 249.09 Million INR | -95.26% |
| 2021 Q4 | 525.63 Million INR | -77.09% |
| 2021 FY | 525.63 Million INR | -61.31% |
| 2021 Q3 | 2.29 Billion INR | 102.4% |
| 2021 Q2 | 1.13 Billion INR | -39.64% |
| 2021 Q1 | 1.87 Billion INR | 38.22% |
| 2020 Q4 | 1.35 Billion INR | 55.03% |
| 2020 Q3 | 876.3 Million INR | -38.08% |
| 2020 FY | 1.35 Billion INR | -22.15% |
| 2020 Q1 | 443.62 Million INR | -74.58% |
| 2020 Q2 | 1.41 Billion INR | 219.04% |
| 2019 Q4 | 1.74 Billion INR | 0.0% |
| 2019 FY | 1.74 Billion INR | 142.75% |
| 2019 Q1 | 198.4 Million INR | -72.4% |
| 2018 FY | 718.9 Million INR | 0.0% |
| 2018 Q4 | 718.9 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | -954.9 Million INR | 115.182% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 158.272% |
| Sigachi Industries Limited | 859.94 Million INR | 83.141% |
| Bal Pharma Limited | 1.26 Billion INR | 88.526% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 103.491% |
| Medico Remedies Limited | 78.67 Million INR | -84.267% |
| Lasa Supergenerics Limited | 205.79 Million INR | 29.555% |
| Venus Remedies Limited | -267.7 Million INR | 154.156% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 115.394% |
| Alpa Laboratories Limited | 35.36 Million INR | -309.965% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 97.645% |
| Shilpa Medicare Limited | 9.06 Billion INR | 98.402% |
| Aarti Drugs Limited | 5.54 Billion INR | 97.387% |
| Lupin Limited | 17.19 Billion INR | 99.157% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 96.075% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 96.294% |
| Windlas Biotech Limited | -273.04 Million INR | 153.097% |
| Suven Life Sciences Limited | -1.63 Billion INR | 108.88% |
| Eris Lifesciences Limited | 13.8 Billion INR | 98.95% |
| Valiant Laboratories Limited | -295.03 Million INR | 149.139% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 94.861% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 98.554% |
| Ipca Laboratories Limited | 11.41 Billion INR | 98.73% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 112.522% |
| Achyut Healthcare Limited | -3.74 Million INR | 3970.155% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 100.2% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 95.605% |
| RPG Life Sciences Limited | -364.7 Million INR | 139.752% |
| Mankind Pharma Limited | -9.9 Billion INR | 101.463% |
| Laurus Labs Limited | 24.38 Billion INR | 99.405% |
| Piramal Pharma Limited | 42.27 Billion INR | 99.657% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -213.726% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 99.545% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 96.25% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 103.383% |
| Unichem Laboratories Limited | 931.91 Million INR | 84.443% |
| Sequent Scientific Limited | 4.17 Billion INR | 96.531% |
| Novartis India Limited | -5.89 Billion INR | 102.461% |
| Wanbury Limited | 1.1 Billion INR | 86.89% |
| Wockhardt Limited | 18.27 Billion INR | 99.206% |
| Themis Medicare Limited | 764.96 Million INR | 81.048% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 110.43% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 99.464% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 105.1% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 98.877% |
| Divi's Laboratories Limited | -39.77 Billion INR | 100.365% |
| NATCO Pharma Limited | -5.81 Billion INR | 102.492% |
| Gufic Biosciences Limited | 3.19 Billion INR | 95.461% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 113.164% |
| Ind-Swift Limited | 9.5 Billion INR | 98.475% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 106.174% |
| FDC Limited | -57.75 Million INR | 351.032% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 92.5% |
| Granules India Limited | 9.28 Billion INR | 98.439% |
| Medicamen Biotech Limited | 160.31 Million INR | 9.569% |
| Alkem Laboratories Limited | -1.6 Billion INR | 109.008% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 102.892% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 885.948% |
| Brooks Laboratories Limited | 49.48 Million INR | -192.97% |
| Megasoft Limited | 1.28 Billion INR | 88.723% |
| ZIM Laboratories Limited | 983.6 Million INR | 85.261% |
| Strides Pharma Science Limited | 23.25 Billion INR | 99.377% |
| Neuland Laboratories Limited | -214.05 Million INR | 167.727% |
| Morepen Laboratories Limited | -231.17 Million INR | 162.713% |
| Hikal Limited | 7.96 Billion INR | 98.18% |
| Indoco Remedies Limited | 6.47 Billion INR | 97.761% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 94.449% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -20.774% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 85.143% |
| Hester Biosciences Limited | 2.29 Billion INR | 93.671% |